一种用于建立更接近临床骨肉瘤的 PDOX 小鼠模型的胫骨原位种植的新方法。
A Novel Procedure for Orthotopic Tibia Implantation for Establishment of a More Clinical Osteosarcoma PDOX Mouse Model.
机构信息
AntiCancer Inc, San Diego, CA, U.S.A.
Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, U.S.A.
出版信息
In Vivo. 2021 Jan-Feb;35(1):105-109. doi: 10.21873/invivo.12237.
Abstract
BACKGROUND/AIM: Osteosarcoma is a rare type of malignancy that affects mostly children and adolescents. A new procedure was designed to create an improved patient-derived orthotopic xenograft (PDOX) mouse model of osteosarcoma that more closely mimics osteosarcoma in clinical settings. Previous osteosarcoma PDOX models involved implanting a tumor fragment near the femur of nude mice in a space created by separating muscle.
MATERIALS AND METHODS
A hole was created in the tibia of nude mice and an osteosarcoma tumor fragment was implanted directly into the bone.
RESULTS
This procedure resulted in tumor growth in the bone similar to osteosarcoma tumors found in clinical patients.
CONCLUSION
The establishment ratio for this procedure is 80% making it a practical and clinically-relevant model for screening effective therapies for osteosarcoma patients.
摘要
背景/目的：骨肉瘤是一种罕见的恶性肿瘤，主要发生在儿童和青少年。本研究设计了一种新的程序，以创建一种改良的患者来源的原位异种移植（PDOX）骨肉瘤小鼠模型，该模型更能模拟临床环境中的骨肉瘤。以前的骨肉瘤 PDOX 模型涉及在裸鼠股骨附近的肌肉间隙中植入肿瘤片段。
材料和方法
在裸鼠的胫骨中钻孔，并将骨肉瘤肿瘤片段直接植入骨中。
结果
该程序导致骨中肿瘤生长类似于临床患者中发现的骨肉瘤肿瘤。
结论
该程序的建立比例为 80%，使其成为一种实用且与临床相关的模型，可用于筛选骨肉瘤患者的有效治疗方法。
相似文献
1
A Novel Procedure for Orthotopic Tibia Implantation for Establishment of a More Clinical Osteosarcoma PDOX Mouse Model.一种用于建立更接近临床骨肉瘤的 PDOX 小鼠模型的胫骨原位种植的新方法。
In Vivo. 2021 Jan-Feb;35(1):105-109. doi: 10.21873/invivo.12237.
2
Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.艾瑞布林在临床精准的骨肿瘤植入人源化小鼠模型中抑制骨肉瘤。
Anticancer Res. 2021 Apr;41(4):1779-1784. doi: 10.21873/anticanres.14943.
3
Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.口服重组甲硫氨酸酶使患者来源的原位异种移植（PDOX）小鼠模型中的骨肉瘤从耐甲氨蝶呤转变为敏感。
Anticancer Res. 2022 Feb;42(2):731-737. doi: 10.21873/anticanres.15531.
4
Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.口服重组蛋氨酸酶在临床相关的患者源性原位异种移植（PDOX）小鼠模型中，可将骨肉瘤从多西他赛耐药转变为敏感。
Anticancer Res. 2021 Apr;41(4):1745-1751. doi: 10.21873/anticanres.14939.
5
Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model.口服重组蛋氨酸酶联合雷帕霉素根除患者来源的原位异种移植小鼠模型中的骨肉瘤。
Anticancer Res. 2022 Nov;42(11):5217-5222. doi: 10.21873/anticanres.16028.
6
Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin.患者来源的原位异种移植（PDOX）小鼠模型中乳腺癌的骨肉瘤被顺铂和埃博霉素同时抑制。
In Vivo. 2021 Nov-Dec;35(6):3107-3110. doi: 10.21873/invivo.12605.
7
The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.顺铂和多柔比星联合治疗 PDX 小鼠模型中的原发性乳腺癌骨肉瘤。
Anticancer Res. 2021 Oct;41(10):4715-4718. doi: 10.21873/anticanres.15285.
8
A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.一种新型的阴离子-磷酸-铂配合物在患者来源的原位异种移植小鼠模型中有效靶向顺铂耐药骨肉瘤。
Cancer Genomics Proteomics. 2020 May-Jun;17(3):217-223. doi: 10.21873/cgp.20182.
9
Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review.骨肿瘤患者来源的原位异种移植（PDOX）模型用于鉴定新型和有效的治疗方法：综述。
Anticancer Res. 2021 Dec;41(12):5865-5871. doi: 10.21873/anticanres.15406.
10
Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.依立布林抑制患者来源的原位异种移植小鼠模型中顺铂和阿霉素耐药复发性肺转移骨肉瘤。
Anticancer Res. 2019 Sep;39(9):4775-4779. doi: 10.21873/anticanres.13661.
引用本文的文献
1
A perspective on patient-derived orthotopic xenograft (PDOX) mouse models for identification of novel and individualized treatment for sarcoma.关于用于肉瘤新型个体化治疗识别的患者来源原位异种移植（PDOX）小鼠模型的观点。
Int J Clin Oncol. 2025 Jun 10. doi: 10.1007/s10147-025-02801-6.
2
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions.组织工程化患者来源骨肉瘤模型解析肿瘤-骨相互作用。
Cancer Metastasis Rev. 2024 Nov 27;44(1):8. doi: 10.1007/s10555-024-10218-2.
3
Progress in building clinically relevant patient-derived tumor xenograft models for cancer research.用于癌症研究的具有临床相关性的患者来源肿瘤异种移植模型构建进展。
Animal Model Exp Med. 2023 Oct;6(5):381-398. doi: 10.1002/ame2.12349. Epub 2023 Sep 7.
4
Fabrication of a composite 3D-printed titanium alloy combined with controlled in situ drug release to prevent osteosarcoma recurrence.制备一种复合3D打印钛合金并结合可控原位药物释放以预防骨肉瘤复发。
Mater Today Bio. 2023 May 24;20:100683. doi: 10.1016/j.mtbio.2023.100683. eCollection 2023 Jun.
5
Non-invasively Imageable Tibia-tumor-fragment Implantation Experimental-bone-metastasis Mouse Model of GFP-expressing Prostate Cancer.可无创成像的含 GFP 表达前列腺癌肿瘤碎片的植入式实验性骨转移小鼠模型。
In Vivo. 2022 Jul-Aug;36(4):1647-1650. doi: 10.21873/invivo.12876.
6
Efficient and Consistent Orthotopic Osteosarcoma Model by Cell Sheet Transplantation in the Nude Mice for Drug Testing.通过裸鼠细胞片移植建立高效且一致的原位骨肉瘤模型用于药物测试
Front Bioeng Biotechnol. 2021 Sep 24;9:690409. doi: 10.3389/fbioe.2021.690409. eCollection 2021.
本文引用的文献
1
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.骨肉瘤的儿科临床前试验联盟的临床前模型中，艾立布林的剂量反应效应。
Pediatr Blood Cancer. 2020 Oct;67(10):e28606. doi: 10.1002/pbc.28606. Epub 2020 Jul 24.
2
Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models.聚腺苷二磷酸核糖聚合酶（PARP）和共济失调毛细血管扩张突变（ATR）抑制剂联合放疗对皮下和原位肺肿瘤模型治疗的差异疗效。
Br J Cancer. 2020 Sep;123(5):762-771. doi: 10.1038/s41416-020-0931-6. Epub 2020 Jun 17.
3
Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma.致癌基因劫持发育转录因子导致尤文肉瘤对氧化应激敏感。
Nat Commun. 2020 May 15;11(1):2423. doi: 10.1038/s41467-020-16244-2.
4
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.PLX3397 治疗抑制组成性 CSF1R 诱导的致癌 ERK 信号，减少骨肉瘤中的肿瘤生长和转移负担。
Bone. 2020 Jul;136:115353. doi: 10.1016/j.bone.2020.115353. Epub 2020 Apr 3.
5
PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.过氧化物酶体增殖物激活受体 γ 激动剂吡格列酮联合顺铂抑制化疗耐药骨肉瘤 PDOX 模型。
Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):35-40. doi: 10.21873/cgp.20165.
6
The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.口服重组甲硫氨酸酶联合阿扎胞苷可抑制化疗耐药骨肉瘤患者来源的原位异种移植小鼠模型。
Cancer Chemother Pharmacol. 2020 Feb;85(2):285-291. doi: 10.1007/s00280-019-03986-0. Epub 2019 Nov 8.
7
Patient-derived orthotopic xenograft models of sarcoma.患者来源的肉瘤原位异种移植模型。
Cancer Lett. 2020 Jan 28;469:332-339. doi: 10.1016/j.canlet.2019.10.028. Epub 2019 Oct 19.
8
Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.吡格列酮是过氧化物酶体增殖物激活受体 γ 的激动剂，通过下调 P-糖蛋白的表达逆转骨肉瘤患者来源的原位异种移植模型中的多柔比星耐药性。
Biomed Pharmacother. 2019 Oct;118:109356. doi: 10.1016/j.biopha.2019.109356. Epub 2019 Aug 22.
9
Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.索拉非尼和依维莫司联合治疗在 DOX 荷瘤鼠模型中逆转多柔比星耐药性骨肉瘤。
Anticancer Res. 2019 Sep;39(9):4781-4786. doi: 10.21873/anticanres.13662.
10
Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma.口服重组甲硫氨酸酶联合口服咖啡因和注射顺铂克服顺铂耐药并使骨肉瘤患者来源的原位异种移植模型消退。
Anticancer Res. 2019 Sep;39(9):4653-4657. doi: 10.21873/anticanres.13646.
Zotero 插件